Cooper Companies (NASDAQ:COO) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Cooper Companies (NASDAQ:COO) announced its quarterly earnings data on Thursday. The medical device company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.04, Zacks reports. The business had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.06 billion. Cooper Companies had a return on equity of 10.01% and a net margin of 9.16%.The business’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same period in the previous year, the company posted $1.04 earnings per share. Cooper Companies updated its FY 2026 guidance to 4.450-4.600 EPS and its Q1 2026 guidance to 1.020-1.040 EPS.

Cooper Companies Price Performance

Shares of COO opened at $81.40 on Friday. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.12 and a quick ratio of 1.24. Cooper Companies has a 1-year low of $61.78 and a 1-year high of $101.53. The stock has a market cap of $16.18 billion, a PE ratio of 43.30, a price-to-earnings-growth ratio of 1.89 and a beta of 1.05. The firm has a fifty day moving average price of $72.29 and a 200 day moving average price of $71.74.

Wall Street Analyst Weigh In

Several research firms have commented on COO. Stifel Nicolaus set a $95.00 price target on shares of Cooper Companies and gave the stock a “buy” rating in a report on Friday. Wells Fargo & Company lifted their price objective on shares of Cooper Companies from $72.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday. JPMorgan Chase & Co. boosted their target price on shares of Cooper Companies from $66.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday. Piper Sandler restated an “overweight” rating and issued a $94.00 price target (up from $83.00) on shares of Cooper Companies in a research note on Friday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $100.00 price target (up from $94.00) on shares of Cooper Companies in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.31.

Cooper Companies announced that its Board of Directors has approved a stock buyback program on Wednesday, September 17th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical device company to purchase up to 15.4% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Insider Activity at Cooper Companies

In other news, Director Lawrence Erik Kurzius bought 2,000 shares of Cooper Companies stock in a transaction dated Monday, September 29th. The stock was acquired at an average cost of $68.39 per share, with a total value of $136,780.00. Following the acquisition, the director owned 5,777 shares of the company’s stock, valued at approximately $395,089.03. This trade represents a 52.95% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.98% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. State Street Corp increased its holdings in shares of Cooper Companies by 1.2% in the second quarter. State Street Corp now owns 8,659,741 shares of the medical device company’s stock valued at $616,227,000 after purchasing an additional 104,910 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Cooper Companies by 332.9% during the third quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock worth $424,043,000 after purchasing an additional 4,756,178 shares during the period. Sustainable Growth Advisers LP grew its position in Cooper Companies by 22.1% in the 3rd quarter. Sustainable Growth Advisers LP now owns 4,132,535 shares of the medical device company’s stock valued at $283,327,000 after buying an additional 747,476 shares during the last quarter. Ameriprise Financial Inc. increased its stake in Cooper Companies by 98.8% in the 2nd quarter. Ameriprise Financial Inc. now owns 3,388,413 shares of the medical device company’s stock valued at $241,120,000 after buying an additional 1,683,561 shares during the period. Finally, UBS Group AG raised its position in Cooper Companies by 47.6% during the 3rd quarter. UBS Group AG now owns 2,660,110 shares of the medical device company’s stock worth $182,377,000 after buying an additional 857,624 shares during the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.